REG - Cizzle Biotechnology - Clinical Study for Lung Cancer Detection in China

Cizzle Biotechnology HoldingsAnnouncement

23/11/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221123:nRSW3340Ha&default-theme=true

RNS Number : 3340H  Cizzle Biotechnology Holdings PLC  23 November 2022

23 November 2022

Cizzle Biotechnology Holdings Plc

 

("Cizzle Biotechnology" or the "Company")

 

Clinical Pilot Study for Early Lung Cancer Detection in China

 

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to
announce that today, at an official signing ceremony at the Chinese Medical
Equipment Fair ("CMEF"), it signed a further Memorandum of Understanding
("MOU") with the International Co-Innovation Centre for Advanced Medical
Technology ("iCCAMT") for a clinical pilot study with the Cancer Hospital
Chinese Academy of Medical Sciences, National Cancer Center of China.  This
follows Cizzle Biotechnology's full commercial agreement with iCCAMT announced
on 3 February 2022.

Background

Lung cancer remains the most prevalent of all cancers in China and resulted in
approximately three million deaths in 2020*.  This creates both a major
health and economic burden with the estimated total national medical cost of
treating lung cancer patients in China estimated to be over US$10 billion **.

Early diagnosis of lung cancer is important in the strategy to detect and
treat the cancer early and the CMEF exhibition is China's largest healthcare
event to highlight the importance of Cizzle Biotechnology's early cancer
biomarker test.

The MOU

The new MOU reflects progress by iCCAMT to implement a clinical pilot study to
evaluate optimised assays using a monoclonal antibody that Cizzle
Biotechnology has developed that specifically detects CIZ1B, which is highly
associated with stage 1 lung cancer.  The initial pilot clinical studies will
be conducted at the Cancer Hospital Chinese Academy of Medical Sciences,
National Cancer Center of China.  These results will have the potential to
provide a platform for developing full commercial tests that can be made
available throughout China.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"In February 2022, we signed a full commercial agreement with our partners
iCCAMT and Intelliphecy to address a major social and economic challenge in
China, lung cancer.  Since that time, we have made significant progress in
developing our reagents and monoclonal antibodies that will enable the
commencement of initial pilot trials with China's leading scientists and
centers of excellence.

"We are delighted to announce this further MOU focused on our clinical trial
programme at CMEF which is the largest HealthTech expo in China, attracting
over 100,000 attendees each year, and bringing together leading international
medical equipment companies, doctors, regulators and government agencies.
(https://www.cmef.com.cn/en (https://www.cmef.com.cn/en) ).  The event had
been delayed because of COVID restrictions in China, but because of the
importance of progressing partnerships in China, the signing ceremony was
conducted virtually."

Commenting, Dr Hui Wu, CEO and Founder of iCCAMT said:

"This new MOU is an important document covering new progress from both sides
and we are now prepared and ready to commence clinical pilot studies. The new
monoclonal CIZ1B antibody developed by our British partner is now being
optimized in assays to be delivered to the National Cancer Center of China in
Beijing, and iCCAMT has been collaborating on the design of a pilot clinical
study proposal with leading clinical researchers from the center. We are
looking forward to continuing our partnership and to securing successful
outcomes in the near future."

 

This announcement contains inside information for the purposes of article 7 of
EU Regulation 596/2014 which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018 ("UK MAR").  Upon the publication of
this announcement this inside information is now considered to be within the
public domain.

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

Notes to Editors:

 

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

About International Co-Innovation Centre for Advanced Medical Technology
("iCCAMT")

iCCAMT, founded with German Medical Valley, Robert Bosch GmbH, and Sinopharm
Group, aims to accelerate global healthcare innovation in China. iCCAMT is
dedicated to support innovative healthcare SMEs (small and medium sized
companies) to grow in China and promote technology transfer. With a global
health technology network and supports from industry giants, iCCAMT has
developed comprehensive platforms to strengthen cross-border health technology
collaborations and help global health technology companies enter the China
market.

For more information, please see http://www.iccamt.com (http://www.iccamt.com)

About the Cancer Hospital, Chinese Academy of Medical Sciences, National
Cancer Centre

The Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS),
is located in the south-eastern part of Beijing. It was built in 1958 and is a
national center of advanced cancer research and treatment, which is also rated
in first place for cancer prevention and treatment in Asia in terms of scale.
It is one of the World Health Organization (WHO) collaborative centers for
cancer research in China and one of the bases for drug clinical trials for the
Food and Drug Administration of State (SFDA). It offers advanced cancer
treatment, engages in cancer research, comprehensive education and
research-based prevention of both common and rare cancers. It is considered a
"state-level hospital" with comprehensive oncology departments, strong
technical force and advanced medical equipment. The major treatments include
surgery, chemotherapy, radiotherapy, biological therapy, intervenient therapy,
and laser therapy.

References

*https://www.statista.com/statistics/1042899/china-new-cancer-case-number

** Fan S, Mao Z, Lee AH, Teh-wei H (2018) Economic Costs of Lung Cancer in
China. Int J Oncol Res 1:007. doi.org/10.23937/ijor-2017/1710007

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREAPFDAEAAFEA